Corcept Therapeutics
Market Cap
US$3.2b
Last Updated
2021/01/15 00:41 UTC
Data Sources
Company Financials +
Executive Summary
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. More Details
Rewards
Risk Analysis
CORT passed our risk checks.
Snowflake Analysis
Flawless balance sheet with solid track record.
Similar Companies
Share Price & News
How has Corcept Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CORT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: CORT's weekly volatility (8%) has been stable over the past year.
Market Performance
7 Day Return
1.5%
CORT
1.6%
US Pharmaceuticals
0.6%
US Market
1 Year Return
110.2%
CORT
2.8%
US Pharmaceuticals
21.0%
US Market
Return vs Industry: CORT exceeded the US Pharmaceuticals industry which returned 2.7% over the past year.
Return vs Market: CORT exceeded the US Market which returned 22% over the past year.
Shareholder returns
| CORT | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.5% | 1.6% | 0.6% |
| 30 Day | 5.5% | 4.4% | 4.2% |
| 90 Day | 53.4% | 8.2% | 12.4% |
| 1 Year | 110.2%110.2% | 6.4%2.8% | 23.7%21.0% |
| 3 Year | 17.1%17.1% | 23.7%14.0% | 47.4%37.6% |
| 5 Year | 663.0%663.0% | 53.2%35.0% | 131.6%105.9% |
Long-Term Price Volatility Vs. Market
How volatile is Corcept Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Is There An Opportunity With Corcept Therapeutics Incorporated's (NASDAQ:CORT) 49% Undervaluation?3 weeks ago | Simply Wall St
Should You Rely On Corcept Therapeutics's (NASDAQ:CORT) Earnings Growth?1 month ago | Simply Wall St
Imagine Holding Corcept Therapeutics (NASDAQ:CORT) Shares While The Price Zoomed 395% HigherValuation
Is Corcept Therapeutics undervalued compared to its fair value and its price relative to the market?
45.3%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CORT ($27.62) is trading below our estimate of fair value ($50.53)
Significantly Below Fair Value: CORT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CORT is poor value based on its PE Ratio (29x) compared to the US Pharmaceuticals industry average (24x).
PE vs Market: CORT is poor value based on its PE Ratio (29x) compared to the US market (21.1x).
Price to Earnings Growth Ratio
PEG Ratio: CORT is poor value based on its PEG Ratio (1.1x)
Price to Book Ratio
PB vs Industry: CORT is overvalued based on its PB Ratio (6.6x) compared to the US Pharmaceuticals industry average (4.3x).
Next Steps
Future Growth
How is Corcept Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
26.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CORT's forecast earnings growth (26.3% per year) is above the savings rate (2%).
Earnings vs Market: CORT's earnings (26.3% per year) are forecast to grow faster than the US market (21.6% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CORT's revenue (15.7% per year) is forecast to grow faster than the US market (10.2% per year).
High Growth Revenue: CORT's revenue (15.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CORT's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Corcept Therapeutics performed over the past 5 years?
40.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CORT has high quality earnings.
Growing Profit Margin: CORT's current net profit margins (30.7%) are higher than last year (30.4%).
Past Earnings Growth Analysis
Earnings Trend: CORT has become profitable over the past 5 years, growing earnings by 40.9% per year.
Accelerating Growth: CORT's earnings growth over the past year (25.9%) is below its 5-year average (40.9% per year).
Earnings vs Industry: CORT earnings growth over the past year (25.9%) exceeded the Pharmaceuticals industry 16.8%.
Return on Equity
High ROE: CORT's Return on Equity (22.3%) is considered high.
Next Steps
Financial Health
How is Corcept Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: CORT's short term assets ($463.5M) exceed its short term liabilities ($43.0M).
Long Term Liabilities: CORT's short term assets ($463.5M) exceed its long term liabilities ($1.4M).
Debt to Equity History and Analysis
Debt Level: CORT is debt free.
Reducing Debt: CORT has no debt compared to 5 years ago when its debt to equity ratio was 217.8%.
Debt Coverage: CORT has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CORT has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Next Steps
Dividend
What is Corcept Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CORT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CORT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CORT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CORT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CORT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.3yrs
Average management tenure
CEO
Joseph Belanoff (63 yo)
22yrs
Tenure
US$4,958,970
Compensation
Dr. Joseph K. Belanoff, M.D., is a Co-Founder of Corcept Therapeutics Incorporated and has been its Chief Executive Officer since 1999 and President since 2014. Dr. Belanoff has been a Faculty Member and h...
CEO Compensation Analysis
Compensation vs Market: Joseph's total compensation ($USD4.96M) is about average for companies of similar size in the US market ($USD4.99M).
Compensation vs Earnings: Joseph's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 22yrs | US$4.96m | 2.15% $ 69.0m | |
| CFO & Secretary | 9.33yrs | US$2.61m | 0.019% $ 599.7k | |
| Chief Commercial Officer | 4.75yrs | US$2.24m | 0.043% $ 1.4m | |
| Chief Medical Officer | 1.83yrs | US$3.90m | 0% $ 0 | |
| Chief Accounting Officer | 0.50yr | no data | no data | |
| Chief Scientific Officer | 1yr | no data | 0.016% $ 524.0k | |
| Director of Investor Relations | no data | no data | no data | |
| Senior Vice President | no data | no data | no data |
3.3yrs
Average Tenure
57yo
Average Age
Experienced Management: CORT's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 22yrs | US$4.96m | 2.15% $ 69.0m | |
| Independent Director | 22yrs | US$234.98k | 4.44% $ 142.5m | |
| Independent Director | 16.5yrs | US$241.66k | 1.04% $ 33.4m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Chairman | 22yrs | US$631.06k | 2.12% $ 68.1m | |
| Independent Director | 5.58yrs | US$248.82k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 0.83yr | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
19.3yrs
Average Tenure
64.5yo
Average Age
Experienced Board: CORT's board of directors are seasoned and experienced ( 19.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CORT insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Corcept Therapeutics Incorporated's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Corcept Therapeutics Incorporated
- Ticker: CORT
- Exchange: NasdaqCM
- Founded: 1998
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$3.209b
- Shares outstanding: 116.17m
- Website: https://www.corcept.com
Number of Employees
Location
- Corcept Therapeutics Incorporated
- 149 Commonwealth Drive
- Menlo Park
- California
- 94025
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CORT | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Apr 2004 |
| HTD | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Apr 2004 |
| 0I3Q | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Apr 2004 |
Biography
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/15 00:41 |
| End of Day Share Price | 2021/01/14 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.